Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics LLC is a veteran and family-owned biotech company with over 35 years of experience in human and animal public health. The company develops diagnostic tools, vaccines, and monoclonal antibodies targeting infectious diseases, antimicrobial resistance, and inflammatory conditions. Core products include PrimeStore® MTM, an FDA-cleared Class II molecular transport media (predicate device) for pathogen inactivation and RNA/DNA preservation in clinical samples; Salorn STM, a virucidal sample collection device for antigen testing; PrimeScreen MTB™, an oral screening kit for tuberculosis detection; PrimeSeqMDR, optimized PCR primers and reagents for MTB resistance gene amplification; and PrimeXtract™, a nucleic acid extraction system. In vaccines and therapeutics, Longhorn develops composite peptide vaccines addressing bacterial sepsis and antimicrobial-resistant infections, and monoclonal antibodies (e.g., LHNVD-501, LHNVD-303) targeting multi-drug resistant bacterial pathogens. The company is recognized by FDA, WHO, USDA, UK Health Department, and NHS. Manufacturing and supply partnerships are based in the United States, ensuring quality and accessibility. Longhorn's products address sample collection, transport, nucleic acid extraction, molecular testing, and therapeutic prevention of infectious and inflammatory disease.